Amina Shah, a fictional 57-year-old school administrator, was offered atorvastatin after cardiovascular-risk assessment. She wants to reduce her chance of myocardial infarction and stroke but has taken three of the last seven doses. She has no muscle symptoms. An online story about rhabdomyolysis frightened her; rotating shifts make the evening dose easy to forget; she recently began an over-the-counter supplement and sometimes uses grapefruit juice. Her repeat prescription is also due while she will be caring for her mother away from home. She expects to be criticised and asks whether taking the tablets irregularly is safer than taking them every day.
No real patient or identifiable patient information is used.- Establish what Amina actually takes, including dose changes, interruptions, non-prescribed products and medicines obtained elsewhere, using a normalising and time-specific approach.
- Distinguish intentional barriers such as beliefs and feared harm from unintentional barriers such as routines, access, dexterity, cognition or regimen complexity.
- Explain personalised benefit, common effects, rare serious harm and uncertainty in a way that supports an informed decision rather than compliance.
- Check clinical safety, interactions and monitoring before simplifying or changing treatment, then match each intervention to an identified barrier.
- Agree one explicit plan with ownership, monitoring, symptom actions, review timing and a method for checking whether it worked.
See the purpose behind each line
Amina, I ask everyone because medicine-taking is difficult for many people and I do not want to make assumptions. In the last seven days, on which days did you take the atorvastatin, and were there any days you changed the dose or decided not to take it?
Normalising, time-bounded behavioural questions elicit partial dosing and deliberate changes more reliably than a yes-or-no adherence question.I took three. Sometimes I forgot after a late shift, and sometimes I chose not to because the muscle-damage story frightened me.
Thank you—that gives us two different problems to solve. Tell me what the story said, what you think the medicine might do to you, and what would make its possible benefit worthwhile. Then we can look separately at the shift pattern.
Belief-driven and practical non-adherence require different interventions; both are explored before advice is offered.I want to avoid a stroke, but I do not want permanent muscle damage. I have no pain now. I also started a supplement, and I drink grapefruit juice most mornings.
The statin is intended to reduce your cardiovascular risk over years; it does not guarantee prevention. Muscle pain can occur, but the extra risk attributable to the statin is small and severe muscle injury is extremely uncommon. If you develop unexplained muscle pain, tenderness or weakness, contact us so we can assess it rather than stopping and restarting repeatedly without a plan. Severe weakness, dark urine or marked illness needs urgent assessment.
The explanation separates purpose, uncertainty, common symptoms, rare serious harm and proportionate action without absolute reassurance.Before we agree anything, I need the name and ingredients of the supplement and a complete list of prescribed, pharmacy and online products. Some medicines, foods and supplements can interact with statins. I will also check that the recommended baseline assessment and follow-up blood tests are complete.
Adherence support does not bypass prescribing safety, interaction review or monitoring.Could I just take it on the evenings I remember?
Irregular self-dosing makes the benefit less reliable and does not give us a clear way to judge tolerance. The options include continuing the agreed daily dose with a routine linked to your shifts, changing the timing if clinically suitable, or reviewing dose or medicine if you develop a genuine problem. Doing nothing for now is also an option, with the consequence that you would not receive the expected risk reduction. Which option fits your priorities?
The clinician compares realistic options, including no treatment, and explains the consequence of intermittent self-adjustment without coercion.I want to try daily treatment. A phone reminder will not help when I am working, but keeping it with my toothbrush might. I need the prescription before I travel.
Our agreed plan is one tablet daily at the clinically agreed time, linked to brushing your teeth; the pharmacy will help arrange supply before travel. You will send the supplement details today and check before starting new medicines or supplements. We will review your lipid profile and liver transaminases two to three months after starting consistently. Contact us sooner for unexplained muscle symptoms, and seek urgent help for severe symptoms or dark urine. Could you talk me through the plan and what you will do if it becomes difficult?
A specific co-designed plan addresses identified barriers, states monitoring and contingency, and uses teach-back to test understanding.Do not label Amina 'non-compliant'. First establish the factual regimen: what she takes, when, how often, any dose reduction or interruption, and every prescribed, non-prescribed, herbal, supplement or externally obtained product. Reconcile this with available records while recognising that dispensing data cannot prove ingestion. Diagnose the barrier before prescribing a solution. Her fear of harm is intentional non-adherence; her rotating shift, travel and supply problem are unintentional barriers. A generic reminder addresses neither unless she says it would help. Explain the medicine's purpose and the likely benefit in the context of her baseline risk, then separate common symptoms, rare serious harm and the action each requires. Do not dismiss online information or invoke a nocebo effect as a reason not to investigate symptoms. For statins, NICE advises that associated muscle symptoms are a small risk and severe muscle effects are extremely rare; unexplained symptoms require assessment and creatine kinase measurement. Check the complete medication and supplement list, interactions, baseline assessment and monitoring before recommending simplification or rechallenge. Offer reasonable options, including no treatment, and document Amina's informed preference. Convert the decision into an operational plan: exact medicine and regimen, linked routine or practical support chosen by her, supply arrangements, what not to change without advice, symptom thresholds, tests, named ownership and a review date. At review, ask again without blame, assess whether the intervention solved the identified barrier, check benefit and harm, and revise the decision if her circumstances or preferences have changed.
What changes the plan?
- Amina reports no symptoms but remains frightened by severe muscle injury: Acknowledge the concern, explain the small attributable muscle-symptom risk and extremely low severe-harm risk, give a concrete symptom action plan and check understanding; do not order routine creatine kinase solely to reassure an asymptomatic person unless another indication exists.
- Amina develops unexplained muscle pain, tenderness or weakness: Assess timing, severity, distribution, alternative causes and interacting substances; follow current guidance on creatine kinase testing and statin management rather than dismissing symptoms or recommending unsupervised stop-start dosing.
- Amina has severe weakness, dark urine or systemic illness: Arrange urgent clinical assessment for possible serious muscle injury and renal complications; pause routine adherence coaching until immediate safety is addressed.
- The supplement or a newly prescribed medicine may interact with atorvastatin: Verify the product and interaction using an authoritative medicines source, assess severity and choose a safe adjustment or alternative with clear temporary instructions and communication to the regular prescriber and pharmacist.
- The main barrier is a rotating shift rather than concern about harm: Co-design a routine, timing or regimen adjustment that is clinically safe and fits her actual day; use reminders, packaging or support only if they target the barrier she identifies.
- Amina cannot obtain the medicine before travelling or cannot afford access in her setting: Treat access as a system problem: clarify supply, eligibility and affordable clinically equivalent options with pharmacy support. Do not misclassify inability to obtain treatment as refusal.
- Amina has difficulty understanding the regimen or remembering multiple medicines: Assess communication needs, cognition, health literacy, dexterity and regimen burden; offer accessible written or visual instructions, interpreter or supporter involvement with consent, medication review and proportionate simplification.
- The medicine is high risk, omission could cause rapid harm or the regimen must not be altered casually: Prioritise immediate risk assessment and specialist or pharmacist advice, give exact missed-dose and escalation instructions from an authoritative source, and ensure closed-loop follow-up rather than applying generic adherence advice.
- Amina makes an informed decision not to take a statin: Respect and document the decision, explain the implications and alternative risk-reduction options, keep the relationship open and arrange review if her risk, evidence, preferences or readiness change.
“Many people miss or change doses sometimes. In the last seven days, what did you actually take?”
“Was that mainly a decision because of concerns, or was something making the plan difficult in practice—or both?”
“Let us separate the expected benefit, common effects, rare serious harms and exactly what to do if symptoms occur.”
“Please include prescribed medicines, pharmacy products, supplements, herbal products and anything obtained online or elsewhere.”
“Which of these options best fits what matters to you, including the option not to start or continue today?”
“Our plan is this exact regimen, this support, these tests and this review date; please tell me how you will carry it out and when you will contact us.”
“You need to be more compliant.”
The label is judgemental, hides the cause of missed doses and treats agreement as obedience rather than an informed decision.“Statins are completely safe.”
Absolute reassurance is inaccurate and deprives the person of a meaningful plan for recognising and responding to harm.“The internet story is nonsense.”
Dismissal damages trust and prevents exploration of the belief driving the decision.“Just use a pill box and an alarm.”
Untargeted interventions fail when the barrier is fear, supply, cost, cognition, dexterity, regimen complexity or an unsafe interaction.“If you refuse, the consequences are your responsibility.”
Coercive blame undermines informed choice, future disclosure and continuity of care.“Take it when you remember.”
Generic advice may be unsafe or ineffective; missed-dose instructions depend on the medicine and must be specific and authoritative.- Recording 'non-adherent' without establishing the actual medicine-taking behaviour and timeframe.
- Failing to distinguish belief-driven decisions from practical barriers or assuming only one cause.
- Quoting relative benefit without baseline context, uncertainty or the option of no treatment.
- Listing adverse effects without their likelihood, seriousness and required action.
- Dismissing reported symptoms or online concerns instead of assessing them and explaining evidence.
- Ignoring prescribed medicines, over-the-counter products, supplements, herbal remedies or medicines obtained elsewhere.
- Offering adherence aids before checking prescribing safety, interactions, monitoring and regimen appropriateness.
- Giving generic missed-dose or stop-start advice for a high-risk or medicine-specific situation.
- Treating supply, affordability, disability, language or cognition as a lack of motivation.
- Ending without an exact regimen, tailored support, monitoring, symptom plan, ownership and review measure.
Test the communication decision
Could I do this reliably?
Choose one recent patient labelled 'non-adherent'. What did you actually establish about behaviour, belief, capability and access—and what specific question would reveal the missing cause next time?
This note stays on this device and is not sent to Clinora.